Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760005 | 0.77 | PLAU (0.40) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL5609802 | 0.76 | CNR1 (0.47) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10546269 | 0.76 | KCNH2 (0.47) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL27514656 | 0.75 | PLAU (0.41) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL13018765 | 0.74 | PLAU (0.46) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL4263924 | 0.74 | CYP2A6 (0.50) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL5757410 | 0.72 | ABCB1 (0.33) | ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4268325 | 0.71 | CYP2A6 (0.47) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL5060028 | 0.71 | ALDH1A1 (0.46) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL10663371 | 0.71 | TRPA1 (0.47) | PLAUCYP2A6F12NCF1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1104412-B1 | TACE INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | claimed |
| US-20030181441-A1 | TACE INHIBITORS | McCLURE Kim (US) | 2003-09-25 | — | — | US | claimed |
| EP-1104403-B1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PROD INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050215549-A1 | TACE inhibitors | MCCLURE KIM F | 2005-09-29 | — | — | US | disclosed |
| EP-1104412-B1 | TACE INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20030181441-A1 | TACE INHIBITORS | McCLURE Kim (US) | 2003-09-25 | — | — | US | disclosed |
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MCCLURE KIM F (US) | 2003-01-09 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| US-6329397-B1 | TREATMENT OF A CONDITION SELECTED FROM THE GROUP CONSISTING OF ARTHRITIS, CANCER, AND OTHER DISEASES CHARACTERIZED BY MATRIX METALLOPROTEINASE OR MAMMALIAN REPROLYSIN ACTIVITY. | PFIZER | 2001-12-11 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1104412-A1 | TACE INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009492-A1 | TACE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181441-A1 | TACE INHIBITORS | ADAMTS5, ADAMTS1, MMP2 | PLAU 355/4885CYP2A6 1588/4885F12 1756/4885 |
| US-20050215549-A1 | TACE inhibitors | ADAMTS5, ADAMTS1, MMP2 | PLAU 393/4885CYP2A6 2026/4885F12 632/4885 |
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | PLAU 370/4885CYP2A6 1957/4885F12 1242/4885 |
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MMP1, MMP10, MMP3 | PLAU 419/4885CYP2A6 2334/4885F12 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.